In this episode of Let’s Talk Future, Jane Ross speaks with Jay Olson, CFA, Managing Director and Senior Analyst covering Biotechnology at Oppenheimer, about healthy aging and the biotech innovation shaping the field.
Rather than focusing on living longer, Jay emphasizes health span: the years people spend healthy, active, and functional. He explains that obesity is closely linked to many diseases of aging, making obesity drugs an important part of the healthy aging conversation.
In this episode of Let’s Talk Future, Jane Ross speaks with Jay Olson, CFA, Managing Director and Senior Analyst covering Biotechnology at Oppenheimer, about healthy aging and the biotech innovation shaping the field.
Rather than focusing on living longer, Jay emphasizes health span: the years people spend healthy, active, and functional. He explains that obesity is closely linked to many diseases of aging, making obesity drugs an important part of the healthy aging conversation.
Join Oppenheimer’s Let’s Talk Future™ podcast as we explore new ways of thinking about the markets, investing, business, new technologies, and life in general.
Oppenheimer & Co. Inc.’s website and/or mobile terms, privacy and security policies don’t apply to the site or app you're about to visit. Please review its terms, privacy and security policies to see how they apply to you. Oppenheimer & Co. Inc. isn’t responsible for (and doesn’t provide) any products, services or content at this third-party site or app, except for products and services that explicitly carry the Oppenheimer & Co. Inc. name.
